The endocannabinoid anandamide regulates the peristaltic reflex by reducing neuro-neuronal and neuro-muscular neurotransmission in ascending myenteric reflex pathways in rats
- 1 April 2014
- journal article
- Published by Springer Nature in Pharmacological Reports
- Vol. 66 (2) , 256-263
Abstract
Endocannabinoids (EC) and the cannabinoid-1 (CB1) receptor are involved in the regulation of motility in the gastrointestinal (GI) tract. However, the underlying physiological mechanisms are not completely resolved. The purpose of this work was to study the physiological influence of the endocannabinoid anandamide, the putative endogenous CB1 active cannabinoid, and of the CB1 receptor on ascending peristaltic activity and to identify the involved neuro-neuronal, neuro-muscular and electrophysiological mechanisms. The effects of anandamide and the CB1 receptor antagonist SR141716A were investigated on contractions of the circular smooth muscle of rat ileum and in longitudinal rat ileum segments where the ascending myenteric part of the peristaltic reflex was studied in a newly designed organ bath. Additionally intracellular recordings were performed in ileum and colon. Anandamide significantly reduced cholinergic twitch contractions of ileum smooth muscle whereas SR141716A caused an increase. Anandamide reduced the ascending peristaltic contraction by affecting neuro-neuronal and neuro-muscular neurotransmission. SR141716A showed opposite effects and all anandamide effects were antagonized by SR141716A (1 μM). Anandamide reduced excitatory junction potentials (EJP) and inhibitory junction potentials (IJP), whereas intestinal slow waves were not affected. CB1 receptors regulate force and timing of the intestinal peristaltic reflex and these actions involve interneurons and motor-neurons. The endogenous cannabinoid anandamide mediates these effects by activation of CB1 receptors. The endogenous cannabinoid system is permanently active, suggesting the CB1 receptor being a possible target for the treatment of motility related disorders.Keywords
This publication has 42 references indexed in Scilit:
- The endocannabinoid system: Its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitationPharmacological Research, 2009
- Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated ratsAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2008
- Targeting the endocannabinoid system: to enhance or reduce?Nature Reviews Drug Discovery, 2008
- Investigation on the relationship between cannabinoid CB1and opioid receptors in gastrointestinal motility in miceBritish Journal of Pharmacology, 2006
- Review article: endocannabinoids and their receptors in the enteric nervous systemAlimentary Pharmacology & Therapeutics, 2005
- Fatty Acid Amide Hydrolase Controls Mouse Intestinal Motility In VivoGastroenterology, 2005
- The endocannabinoid system: a general view and latest additionsBritish Journal of Pharmacology, 2004
- Localisation of cannabinoid CB1 receptor immunoreactivity in the guinea pig and rat myenteric plexusJournal of Comparative Neurology, 2002
- Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in miceBritish Journal of Pharmacology, 2001
- Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea‐pig myenteric plexusBritish Journal of Pharmacology, 1997